Latest Breaking News On - Joaquim bellmunt - Page 1 : comparemela.com

Health care professionals celebrate 'milestone' FDA approval for HER2-positive solid tumors

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors. The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) — a HER2-directed antibody-drug conjugate previously approved

Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023